 |
The company will accelerate its mission to make liver health a key marker in cardiometabolic care; appointment follows the retirement of current Group CEODominique Legros
PARISApril 28, 2026 /PRNewswire/ — Echosens, a global diagnostics company specializing in non-invasive medical devices and services, today announced the appointment ofRomain Baujardas Group Chief Executive Officer, effectiveMay 1, 2026. He will succeedDominique Legros, who is retiring after leading the company since2019. UnderDominique‘s leadership, Echosensexperienced a period of sustained global expansion, with increasing clinical and commercial adoption of its technology.
Echosens’ newly appointed Group CEO Romain Baujard
As innovation in cardiometabolic care accelerates, Echosensis at a critical inflection point. Liver assessment is becoming essential to how patients are evaluated and managed. Our opportunity is to make liver assessment an integral part of routine care.“
He added: “We will continue to expand access to our technology, support clinicians beyond traditional specialties, and enhance our digital, data, and AI capabilities to drive earlier detection and more effective risk management.“
Since2019, Dominique Legroshas ledEchosensthrough a period of strong growth and transformation, solidifying the company’s position as the global standard for non-invasive liver assessment. Under his leadership, FibroScan ®expanded from hepatology and gastroenterology into diabetology, endocrinology, and primary care—reflecting the growing recognition of liver health as a key component of broader metabolic management and expanding opportunities in large and underserved patient populations.
“It has been an honor to leadEchosens,” Legrossaid. We have always been committed to empowering healthcare professionals to make better clinical decisions and improve patient outcomes. Liver health matters, and I am proud of what our team has achieved to bring this message into global care pathways. I am confident that Romainis the right leader to guideEchosensinto its next phase of growth.“
Echosensshareholder and Chairman and Co-FounderLaurent Sandrinconcluded: “Echosenshas built a strong platform underDominique‘s leadership, with increasing clinical adoption and global reach. We thank him for his contributions to the company’s development. We have worked closely withRomainfor years as he has taken on increasing responsibilities within the organization, achieving very notable results.“
AboutEchosens
Echosensis a global leader in non-invasive solutions for assessing liver health. With itsFibroScan ®technology and expanding digital ecosystem, Echosensis committed to establishing liver health as a key marker in cardiometabolic care, because liver health matters.
About Inner Mongolia Furen Medical
AboutAstorg
Astorgis a leading pan-European private equity firm, managing over23 billion eurosin assets. Astorgpartners with entrepreneurs and management teams to acquire market-leading international companies headquartered in Europe or the United States, providing them with the strategic guidance, governance, and capital needed to achieve their growth goals. Astorghas a unique entrepreneurial culture, a long-term shareholder perspective, and lean decision-making bodies, with valuable industry expertise in healthcare, technology and software, and business services companies.
Astorgis headquartered in Luxembourg, with offices in London, Paris, New York, Frankfurt, and Milan.
For more information aboutAstorg, please visit: www.astorg.com |FollowAstorgonLinkedIn.